Back to all studiesUnknownNCT06542445
The Safety and Efficacy of Terpene-enriched Cannabidiol (CBD) Oil in ADHD
Official study titleThe Safety and Efficacy of Treatment With Cannabidiol (CBD) Oil Enriched With Terpenes, Devoid of THC, in Children Diagnosed With ADHD
Medication studyAges 6–18Israel
The study in practiceUnderstand this study
Who could participate?
Listed age limits: 6 years to 18 years.
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
What to know before participating
A point to clarifyThis summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Study clarityThings to check before joining
Study start dateStarted: August 22, 2024
- Recruitment status
- Unknown
- Enrollment listed in the registry
- 120
- Sponsor
- Bazelet Nehushtan LtD.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Israel
- Age range
- From 6 Years to 18 Years
- Official registry ID
- NCT06542445
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT06542445. We help you review the study, but cannot decide medical eligibility.
A listed location does not confirm current availability.
FAQQuestions about this study
Who is behind this study?
The study sponsor is Bazelet Nehushtan LtD.
Does this study involve medication?
Yes. The study involves medication, including Oral CBD oil enriched with terpenes and Oral Placebo.
Who can participate?
Listed age limits: 6 years to 18 years.
Explore other studiesWant to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me